Cognito Therapeutics, Inc.

In the latest episode of our podcast, Christian Howell, Chief Commercial Officer at Cognito Therapeutics, shares his experience in implementing value-based healthcare models and offers unique perspectives on driving innovation while developing novel therapies. 🎙️ Learn about: 🔹 The importance of stakeholder engagement in healthcare innovation 🔹 Fostering a culture of smart risk-taking and learning from failures 🔹 Practical lessons for innovation from value-based healthcare models 🔗 Listen now: https://lnkd.in/dv-3YCRh

Our Chief Commercial Officer Christian Howell spoke with SSI Strategy about Cognito's evidence generation strategy to demonstrate the value of their non-invasive neural stimulation therapy. "It's critical to bring all the key players to the table early and be fully transparent about your data - that's how you build trust and alignment around value." Listen to the podcast here: https://lnkd.in/dc-gKaXp

Excited to share our CSO Mihaly Hajos will be presenting a talk on July 27th at #AAIC24: "Evoked Gamma Oscillation (Spectris) as a Potential Therapeutic Intervention for Alzheimer's Disease." Hope you can join us at the Alzheimer's Association®International Conference later this month! #Alzheimers #cognition #neuroscience

We will be presenting at the Alzheimer's Association® International Conference 2024. 🧠🧠🧠 “We are excited to share our latest data demonstrating the potential of our non-invasive neuromodulation therapy to slow Alzheimer’s disease progression and result in time saved,” said Ralph Kern, M.D. MHSc, Chief Medical Officer, Cognito Therapeutics. “By modifying synaptic and myelin proteins and reducing white matter and brain volume loss, our disease-modifying therapy may play a key role in maintaining brain function. We look forward to presenting our latest clinical research findings and their implications for future treatments with the global Alzheimer's research community at #AAIC24.” Read the release: https://lnkd.in/ed5GF8Nt

Terrific discussion on what it takes to progress science with Teresa Bitetti Takeda Sekar (Sek) Kathiresan Verve Therapeutics John Lepore ProFound Therapeutics Søren Møller Novo Holdings Joanna Stanicka Axonis Therapeutics Brent Vaughan Cognito Therapeutics, Inc.

June is #Alzheimers and #BrainAwareness month! 🧠🧠🧠 Worldwide, more than 55 million people are living with Alzheimer's or another dementia. Take action now — for yourself, your loved ones and for the fight to end Alzheimer's. What actions can you commit to taking this month? Purple is the official color of the Alzheimer's movement. Wear and share purple throughout June to spread awareness and invite others to join the fight to end Alzheimer's. Use #ENDALZ and share why you raise awareness for Alzheimer’s. Learn what our team at Cognito is working on: https://www.cognitotx.com/ More info from Alzheimer's Association®: https://lnkd.in/dRjuh-U

What are the headwinds, tailwinds, and opportunities in neuromodulation and neurodegenerative disease? Catch the full #LSIUSA24 panel recording, now live on our website and YouTube channel. This discussion features leading innovators and strategics exploring the complexities of the brain, addressing the challenges, and identifying opportunities in advancing neuromodulation and combating neurodegenerative diseases. Tune in to, “The Decade of Brain Health: Headwinds, Tailwinds, and Opportunities in Neuromodulation and Neurodegenerative Disease” to hear from this incredible group of panelists: • Mike Labbe (Moderator) — Velentium • Kip Roberts — Medtronic • Ken Mariash — Sinaptica Therapeutics • Ana Maiques — Neuroelectrics • Brent Vaughan — Cognito Therapeutics, Inc. Want to see more content like this? Registration and applications to present are open for LSI Europe ‘24 this September 16th - 20th at the Penha Longa Resort, in Portugal. Secure your spot today to ensure you get the best rate.

Our Chief Scientific Officer Mihaly Hajos will be speaking at the 5th Annual Symposium on Alzheimer’s and Dementia. Title: Evoked Gamma Oscillation as a Potential Therapeutic Intervention for Alzheimer’s Disease More info here: https://lnkd.in/eXYehBnG

We’re excited to announce a poster presentation at the ISPOR—The Professional Society for Health Economics and Outcomes Research 2024 Meeting, held May 5-8 in Atlanta, GA. The presented research is a targeted literature review of the clinical, humanistic, and economic burden of #Alzheimer’s Disease. “In light of the continued rise in projected Alzheimer's cases, this comprehensive review underscores the profound impact of mild-to-moderate AD and MCI on patients, caregivers, and healthcare systems,” said Ralph Kern, MD, MHSc, Chief Medical Officer, Cognito Therapeutics. “This analysis reveals a number of factors influencing disease progression, quality of life, and healthcare resource utilization. The results highlight the need to better address and help AD patients proactively by developing novel disease-modifying therapies to alleviate the massive burden on the healthcare system.” Details of the poster presentation: Title: A Targeted Literature Review of Clinical, Humanistic, and Economic Burden of Alzheimer’s Disease in the United States Presenter: Lily Lee, Ph.D., VP, Medical Affairs, Cognito Therapeutics Poster Session: Poster Session 1 Poster Code: EPH39 Presentation Date/Time: Monday, May 6, 2024, 10:30 AM-1:30PM Discussion Period: 12:30PM-1:30PM Read the release: https://lnkd.in/exTr5Udp

“This innovative therapy has the potential to be seamlessly integrated as a home-based treatment into the lives of patients and caregivers.” Cognito Therapeutics, Inc. #neuromodulation #digitalhealth #medtech #meddevice #Alzheimers